文献速递消化系统肿瘤

肝移植后肝细胞癌复发风险估计(RETREAT)评分的验证

Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
PubMed 文献 · JAMA Oncol · 2017-01-01

该研究在721例符合米兰标准的肝移植患者中建立RETREAT评分,并在341例多伦多队列中验证。评分基于微血管侵犯、甲胎蛋白和移植肝存活肿瘤总直径与数目,C统计量为0.77,验证队列为0.82,可区分5年复发风险从低于3%到高于75%。

要点

  • RETREAT评分由微血管侵犯、移植时甲胎蛋白、移植肝存活肿瘤总直径与数目构成,分值0至5分或更高。
  • 开发队列C统计量0.77,验证队列C统计量0.82(95%CI 0.77-0.86)。
  • 评分0分者5年复发风险低于3%,5分或更高者高于75%。

核心结论

  • 研究开发并验证了一种简易的新型预后评分,可能改善肝移植后肝细胞癌监测策略,并帮助识别可能从未来辅助治疗中获益的患者。

研究设计与样本

  • 开发队列为2002年至2012年在3家学术移植中心(加利福尼亚大学旧金山分校、罗切斯特梅奥诊所、杰克逊维尔梅奥诊所)接受肝移植的721例影像学符合米兰标准的患者,用于建立RETREAT评分。
  • 验证队列为在多伦多移植中心接受肝移植的341例影像学符合米兰标准的患者,使用C统计量和净重分类指数进行验证。

主要发现

  • 开发队列721例(542例男性)移植时甲胎蛋白中位水平为8.3 ng/mL,9.4%有微血管侵犯(n=68),22.1%因移植前影像分期不足而移植肝超出米兰标准(n=159)。
  • 开发队列肝细胞癌复发1年和5年累积概率分别为5.7%和12.8%。
  • 多变量Cox比例风险回归中,微血管侵犯、移植时甲胎蛋白、移植肝存活肿瘤最大直径与存活肿瘤数目之和3个变量与肝细胞癌复发独立相关。
  • 验证队列340例(283例男性)微血管侵犯(23.8% [n=81],P < .001)、移植肝超出米兰标准(37.3% [n=159],P < .001)和5年肝细胞癌复发(17.9% [n=159],P = .03)均显著高于开发队列。
  • 验证队列中RETREAT评分区分度良好(C统计量0.82;95%CI 0.77-0.86),且复发风险分类优于移植肝米兰标准(净重分类指数0.40;P = .001)。

关键数值与推荐

  • RETREAT评分使用微血管侵犯、移植时甲胎蛋白、移植肝存活肿瘤最大直径与存活肿瘤数目之和3个变量,分值范围0至5分或更高。
  • 开发队列中RETREAT评分对肝细胞癌复发有高度预测性(C统计量0.77),可将5年移植后复发风险从评分0分的低于3%分层至评分5分或更高的高于75%。

临床怎么用

  • 作者认为该评分可能改善肝移植后肝细胞癌监测策略,并帮助识别可能从未来辅助治疗中获益的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Several factors are associated with increased hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT), but no reliable risk score has been established to determine the individual risk for HCC recurrence. OBJECTIVE: We aimed to develop and validate a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for patients with HCC meeting Milan criteria by imaging. DESIGN, SETTING, AND PARTICIPANTS: Predictors of recurrence were tested in a development cohort of 721 patients who underwent LT between 2002 and 2012 at 3 academic transplant centers (University of California-San Francisco; Mayo Clinic, Rochester; and Mayo Clinic, Jacksonville) to create the RETREAT score. This was subsequently validated in a cohort of 341 patients also meeting Milan criteria by imaging who underwent LT at the University of Toronto transplant center using the C concordance statistic and net reclassification index. MAIN OUTCOMES AND MEASURES: Characteristics associated with post-LT HCC recurrence. RESULTS: A total of 1061 patients participated in the study; 77.8% (825) were men, and the median (IQR) age was 58.2 (53.3-63.9) years in the development cohort and 56.4 (51.7-61.0) years in the validation cohort (P < .001). In the development cohort of 721 patients (542 men), median α-fetoprotein (AFP) level at the time of LT was 8.3 ng/mL; 9.4% had microvascular invasion (n = 68), and 22.1% were beyond Milan criteria on explant (n = 159) owing to understaging by pretransplantation imaging. Cumulative probabilities of HCC recurrence at 1 and 5 years were 5.7% and 12.8%, respectively. On multivariable Cox proportional hazards regression, 3 variables were independently associated with HCC recurrence: microvascular invasion, AFP at time of LT, and the sum of the largest viable tumor diameter and number of viable tumors on explant. The RETREAT score was created using these 3 variables, with scores ranging from 0 to 5 or higher that were highly predictive of HCC recurrence (C statistic, 0.77). RETREAT was able to stratify 5-year post-LT recurrence risk ranging from less than 3% with a score of 0 to greater than 75% with a score of 5 or higher. The validation cohort (n = 340; 283 men) had significantly higher microvascular invasion (23.8% [n = 81], P < .001), explant beyond Milan criteria (37.3% [n = 159], P < .001), and HCC recurrence at 5 years (17.9% [n = 159], P = .03). RETREAT showed good model discrimination (C statistic, 0.82; 95% CI, 0.77-0.86) and superior recurrence risk classification compared with explant Milan criteria (net reclassification index, 0.40; P = .001) in the validation cohort. CONCLUSIONS AND RELEVANCE: We have developed and validated a simple and novel prognostic score that may improve post-LT HCC surveillance strategies and help identify patients who may benefit from future adjuvant therapies.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mehta N, Heimbach J, Harnois DM, et al. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017. PMID: 27838698. doi:10.1001/jamaoncol.2016.5116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。